Chemical Structure (Myfembree 01)
Myfembree Tablet, Film Coated
Product Images NDC 72974-415
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Myfembree (NDC 72974-415). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sumitomo Pharma America, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Myfembree 02)
Chemical Structure (Myfembree 03)
Figure 1 L1 (Myfembree 04)
Figure 1 L2 (Myfembree 05)
The text represents a table showing the "Least Squares Mean Percent Change" of two groups (MYFEMBREE and Placebo) over a period of 24 weeks. The table includes values at baseline, week 4, week 12, week 16, week 20, and week 24. However, there is no indication about the nature of the percent change or the variable of interest, so any further interpretation is not possible.*
Principal Display Panel (28 Tablet Bottle Label)
Myfembree is a prescription drug with NDC code 72974-415-01. It contains 40mg Relugolix, 1mg Estradiol, and 0.5mg Norethindrone Acetate per tablet. It comes in 28 tablets pack with dosages mentioned in the prescribing information. It is advised to store the medicine between 15°C to 30°C (59°F - 86°F). Myfembree is distributed by Myovant Sciences, Inc. based in Brisbane, CA, and manufactured in Canada. Please keep this medicine away from children and do not flush any unused medicine.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
